| Literature DB >> 21103362 |
Alexia Cusini1, Silvana K Rampini, Vineeta Bansal, Bruno Ledergerber, Stefan P Kuster, Christian Ruef, Rainer Weber.
Abstract
BACKGROUND: Unnecessary or inappropriate use of antimicrobials is associated with the emergence of antimicrobial resistance, drug toxicity, increased morbidity and health care costs. Antimicrobial use has been reported to be incorrect or not indicated in 9-64% of inpatients. We studied the quality of antimicrobial therapy and prophylaxis in hospitalized patients at a tertiary care hospital to plan interventions to improve the quality of antimicrobial prescription. METHODOLOGY/PRINCIPALEntities:
Mesh:
Substances:
Year: 2010 PMID: 21103362 PMCID: PMC2982822 DOI: 10.1371/journal.pone.0014011
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Patient characteristics.
| Characteristics | Total | Surgical wards | Medical wards | ICU | Haemato-oncology wards |
| No. of evaluated patients (%) | 1577 (100) | 543 (34.4) | 553 (35.1) | 294 (18.6) | 187 (11.9) |
| Female | 625 (39.6) | 248 (45.7) | 211 (38.2) | 101 (34.4) | 65 (34.8) |
| Male | 952 (60.4) | 295 (54.3) | 342 (61.8) | 193 (65.6) | 122 (65.2) |
| Mean age (range) | 57.6 (16–98) | 56.0 (16–95) | 60.4 (16–98) | 58.5 (15–94) | 55.9 (17–90) |
| Mean days of hospital stay at time of evaluation (range) | 7.2 (0–180) | 5.0 (0–111) | 6.8 (0–180) | 6.0 (0–102) | 7.8 (1–71) |
| No. of patients with ICU stay during hospitalisation (%) | 508 (32.2) | 136 (25.0) | 68 (12.3) | 294 (100) | 10 (5.3) |
| No. of immunocompromised patients | 366 (23.2) | 41 (7.6) | 150 (27.1) | 37 (12.6) | 138 (73.8) |
| Mean Charlson comorbidity index (range) | 2.7 (0–11) | 1.76 (0–11) | 2.99 (0–10) | 3.27 (0–11) | 3.68 (2–10) |
| Patient no. with comorbidity index = 0 (%) | 354 (22.5) | 248 (45.7) | 66 (11.9) | 40 (1.6) | 0 (0) |
| Comorbidity index = 1–2 | 552 (35.0) | 150 (27.6) | 206 (37.3) | 97 (33.0) | 99 (52.9) |
| Comorbidity index = 3–4 | 288 (18.3) | 61 (11.2) | 138 (25.0) | 68 (23.1) | 21 (11.2) |
| Comorbidity index = ≥5 | 383 (24.3) | 84 (15.5) | 143 (25.9) | 89 (30.3) | 67 (35.8) |
| Patients on antimicrobials (%) | 700 (44.4) | 196 (36.1) | 255 (46.1) | 142 (48.3) | 107 (57.2) |
| Patients on therapy | 568 (36.0) | 167(30.8) | 208 (37.6) | 113 (38.4) | 80 (42.8) |
| Patients on prophylaxis | 228 (14.5) | 33 (6.1) | 88 (15.9) | 38 (12.9) | 69 (36.9) |
| Total no. of prescriptions (%) | 1270 (100) | 258 (20.3) | 460 (36.2) | 224 (17.6) | 328 (25.8) |
| Prescriptions for therapy | 958 (75.4) | 211 (81.8) | 354 (77) | 179 (79.9) | 214 (65.2) |
| Prescriptions for prophylaxis | 312 (24.6) | 47 (18.2) | 106 (23.0) | 45 (20.1) | 114 (34.8) |
| Prescriptions for surgical prophylaxis | 60 (19.2) | 20 (42.5) | 16 (15.1) | 24 (53.3) | 0 (0) |
| Prescriptions for prophylaxis in immunocompromised patients | 252 (80.8) | 27 (57.5) | 90 (84.9) | 21 (46.7) | 114 (100) |
Immunosupression includes patients with transplantation, splenectomy, immunosuppressive therapy or steroids, agammaglobulinaemia and cellular immunodeficiency.
Top ten antimicrobial drugs for treatment in different hospital units: No. (%) of prescriptions.
| Surgical wards | Medical wards | ICU | Haemato-oncology wards | ||||
| Total no. (%) | 211 (100) | Total no. (%) | 354 (100) | Total no. (%) | 179 (100) | Total no. (%) | 214 (100) |
| Amoxicillin-clavulanate | 85 (40.3) | Piperacillin-tazobactam | 58 (16.4) | Piperacillin-tazobactam | 32 (17.9) | Piperacillin-tazobactam | 25 (11.7) |
| Ciprofloxacin | 32 (15.2) | Amoxicillin-clavulanate | 38 (10.7) | Amoxicillin-clavulanate | 31 (17.3) | Aciclovir | 23 (10.7) |
| Piperacillin-tazobactam | 19 (9.0) | Ceftriaxone | 24 (6.8) | Meropenem | 23 (12.8) | Meropenem | 19 (8.9) |
| Metronidazole | 14 (6.6) | Ciprofloxacin | 21 (5.9) | Vancomycin | 23 (12.8) | Amoxicillin-clavulanate | 15 (7.0) |
| Rifampicin | 6 (2.8) | Metronidazole | 18 (5.1) | Ciprofloxacin | 10 (5.6) | Ciprofloxacin | 13 (6.1) |
| Trimethoprim-sulfamethoxazole | 5 (2.4) | Valaciclovir | 15 (4.2) | Ceftriaxone | 8 (4.5) | Voriconazole | 13 (6.1) |
| Ceftriaxone | 4 (1.9) | Levofloxacin | 10 (2.8) | Fluconazole | 8 (4.5) | Caspofungin | 12 (5.6) |
| Clindamycin | 4 (1.9) | Fluconazole | 9 (2.5) | Clindamycin | 8 (4.5) | Metronidazole | 10 (4.7) |
| Cefuroxime | 4 (1.9) | Clarythromycin | 9 (2.5) | Moxifloxacin | 8 (4.5) | Cefepime | 9 (4.2) |
| Fluconazole | 3 (1.4) | Meropenem | 6 (1.7) | Metronidazole | 6 (3.4) | Valaciclovir | 9 (4.2) |
| Other | 35 (16.6) | Other | 146 (41.2) | Other | 22 (12.3) | Other | 66 (30.8) |
Main indications for antimicrobial therapy.
| Total | Surgical wards | Medical wards | ICU | Oncology, haematology wards | |
| Total no. of diagnoses (%) | 648 (100) | 167(100) | 208 (100) | 113 (100) | 160 (100) |
| Respiratory tract infection | 138 (21.3) | 12 (7.2) | 64 (30.7) | 31 (27.4) | 31 (19.4) |
| Peritonitis | 43 (6.6) | 21(12.6) | 7 (3.4) | 12 (10.6) | 3 (1.9) |
| Sepsis, bacteraemia | 42 (6.5) | 6 (3.69 | 9 (4.3) | 20 (17.7) | 7 (4.4) |
| Skin, soft tissue infection | 41 (6.3) | 10 (6.0) | 23 (11.1) | 2 (1.8) | 6 (3.9) |
| Fever in neutropenia | 35 (5.4) | 0 (0) | 7 (3.4) | 0 (0) | 28 (18.2) |
| Infection of unclear origin | 34 (5.2) | 7 (4.2) | 9 (4.3) | 6 (5.3) | 12 (7.5) |
| Gastrointestinal tract infection | 32 (4.9) | 3 (1.5) | 18 (8.7) | 2 (1.8) | 9 (5.8) |
| Postoperative wound infection | 31 (4.8) | 25 (15.0) | 0 (0) | 6 (5.3) | 0 (0) |
| Traumatic wound/open fracture | 29 (4.5) | 24 (14.4) | 0 (0) | 5 (4.4) | 0 (0) |
| Pulmonary aspergillosis | 25 (3.9) | 0 (0) | 5 (2.4) | 0 (0) | 20 (13.0) |
| Cardiovascular infection | 20 (3.1) | 0 (0) | 13 (6.2) | 7 (6.2) | 0 (0) |
| Urinary tract infection | 19 (2.9) | 0 (0) | 15 (7.2) | 1 (0.9) | 3 (1.9) |
| Herpes simplex virus | 19 (2.9) | 0 (0) | 0 | 0 (0) | 19 (12.3) |
| Hepatitis | 10 (1.5) | 0 (0) | 8 (3.8) | 1 (0.9) | 1 (0.6) |
| Infections with Candida | 7(1.1) | 0 (0) | 0 (0) | 0 (0) | 7 (4.4) |
| Other | 51 (7.9) | 16 (9.6) | 22 (10.6) | 5 (4.4) | 8 (5.0) |
| No infection | 72 (11.1) | 43 (25.7) | 8 (3.8) | 15 (13.3) | 6 (3.8) |
In the surgical and medical wards and ICUs we documented the leading infection whereas in the haemato-oncology wards all infections occurring during the hospitalisation were documented.
Evaluation of the appropriateness of antimicrobial treatment and prophylaxis.
| Total | Surgical wards | Medical wards | ICU | Haemato-oncology wards | |||
|
| No. of patients with antimicrobial therapy | 568 | 167 | 208 | 113 | 80 | |
| No. of prescriptions (%) | 958 (100) | 211 (100) | 354 (100) | 179 (100) | 214 (100) | ||
| Total no. of inappropriate prescriptions | 354 (37.0) | 104 (49.3) | 115 (32.9) | 58 (32.4) | 77 (36.0) | ||
| Inappropriate indication | Total | 168 (17.5) | 64 (30.3) | 41 (11.6) | 33 (18.4) | 30 (14.0) | |
| No infection | 101 (10.6) | 57(27.0) | 16 (4.5) | 21 (11.7) | 7 (3.2) | ||
| Infection, no antimicrobials needed | 67 (7.0) | 7 (3.3) | 25 (7.1) | 12 (6.7) | 23 (10.7) | ||
| Inappropriate choice | Total | 73 (7.6) | 23 (10.9) | 30 (8.4) | 14 (7.8) | 6 (2.8) | |
| Spectrum too broad | 31 (3.2) | 5 (2.3) | 19 (5.3) | 7 (3.9) | 0 (0) | ||
| Spectrum too narrow | 16 (1.7) | 7 (3.3) | 2 (0.6) | 2 (1.1) | 5 (2.3) | ||
| Spectrum ineffective | 24 (2.5) | 11 (5.2) | 9 (2.5) | 3 (1.6) | 1 (0.5) | ||
| Inappropriate toxicity profile | 2 (0.2) | 0 (0) | 0 (0) | 2 (1.1) | 0 (0) | ||
| Inappropriate application | Total | 89 (9.3) | 20 (9.5) | 35 (9.9) | 12 (6.7) | 22 (10.3) | |
| Dosage | 31 (3.2) | 2 (9.5) | 12 (3.4) | 7 (3.9) | 10 (4.7) | ||
| Timing | 20 (2.1) | 1 (0.5) | 14 (4.0) | 2 (1.1) | 3 (1.4) | ||
| Route of administration | 9 (0.9) | 3 (1.4) | 3 (0.8) | 1 (0.6) | 2 (1.8) | ||
| Duration too long | 29 (3.0) | 14 (6.6) | 6 (1.6) | 2 (1.1) | 7 (3.3) | ||
| Divergence from internal guidelines | 77 (8.0) | 2 (0.9) | 39 (11.0) | 12 (6.7) | 24 (11.2) | ||
| Data insufficient for evaluation of appropriateness | 23 (2.4) | 0 (0) | 9 (2.5) | 6 (3.4) | 8 (3.7) | ||
|
| No. of patients with antimicrobial prophylaxis | 228 | 33 | 88 | 38 | 69 | |
| No. of prescriptions (%) | 312 (100) | 47 (100) | 106 (100) | 45 (100) | 114 (100) | ||
| Total no. of inappropriate prescriptions | 52 (16.6) | 6 (12.8) | 17 (16.0) | 16 (35.6) | 13 (11.4) | ||
| Inappropriate indication | 28 (9.0) | 1 (2.1) | 10 (9.4) | 8 (17.8) | 9 (7.9) | ||
| Inappropriate spectrum | 3 (1.0) | 0 (0) | 1 (0.9) | 2 (4.4) | 0 (0) | ||
| Inappropriate application | Total | 21 (6.7) | 5 (10.6) | 6 (5.6) | 6 (13.3) | 4 (3.5) | |
| Duration too long | 16 (5.1) | 5 (10.6) | 6 (5.6) | 5 (11.1) | 0 (0) | ||
| Dosage/timing | 4 (1.3) | 0 (0) | 0 (0) | 1 (2.2) | 4 (3.5) | ||
*One prescription can include more than one inappropriate decision.
Appropriateness of empiric, directed, and targeted prescriptions.
| Therapy | Total | Surgical wards | Medical wards | ICU | Hemato-oncology wards |
| Total no. of prescriptions | 958 | 211 | 354 | 179 | 214 |
| Empiric prescriptions | 688 (100) | 152 (100) | 238 (100) | 117 (100) | 181 (100) |
| Inappropriate | 292 (42.6) | 92 (60.5) | 92 (38.7) | 48 (41.0) | 60 (33.2) |
| Directed prescriptions | 97 (100) | 12 (100) | 75 (100) | 10 (100) | n.a. |
| Inappropriate | 22 (22.7) | 2 (16.7) | 16 (21.3) | 4 (40.0) | n.a. |
| Targeted prescriptions | 173 (100) | 47 (100) | 41 (100) | 52 (100) | 33 (100) |
| Inappropriate | 32 (18.5) | 10(21.3) | 7(17.1) | 9 (17.3) | 6 (18.2) |
*Prescriptions were classified as ‘empirical’ when the pathogen was unknown at the time of prescription, as ‘directed’ when the pathogen was suspected based on provisional microbiological result (such as Gram stain), and as ‘targeted’ when a pathogen was identified.
**n.a. = not applicable. In the haemato-oncology wards we did not differentiate between empirical and directed therapy because in neutropenic patients empirical therapy is rarely adapted to tentative microbiological results.